Summit Therapeutics Stock
Summit Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert W. Duggan
- Employees
- 265
- Market cap
- $11.7 B
- IPO
- 05/03/2015
Summit Therapeutics Inc. is a biopharmaceutical company operating in the healthcare/biotechnology sector, based in Cambridge, Massachusetts. Founded in 2003, the company is dedicated to the discovery and commercialization of therapeutic solutions for infectious diseases. A core focus lies in the development of…
AI-generated company profile based on the figures on this page, last updated on 01/09/2026. Not investment advice.
Summit Therapeutics stock: price history
1D
-4.8%
1W
-16.8%
1M
-15.4%
6M
-41.8%
YTD
-16.4%
1Y
-33.4%
2Y
-37.6%
5Y
+184.1%
10Y
+36.6%
Next earnings date
Next earnings date
19/10/2026 (in 2 days)
Volatility around earnings
~2% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Summit Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Summit Therapeutics Inc. is a biopharmaceutical company pursuing the development and commercialization of therapies against infectious diseases, with a focus on treating Clostridioides difficile infections (CDI), where the active ingredient Ridinilazole is in Phase III clinical trials. The portfolio additionally encompasses approaches to combat multidrug-resistant pathogens such as carbapenem-resistant Enterobacteriaceae. Currently, revenues are generated entirely through licensing fees and services in the Latin American region.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Summit Therapeutics
Analyst assessment of Summit Therapeutics
PRICE TARGET LOW
US$16.00
CONSENSUS
US$29.33
MEDIAN
US$30.00
PRICE TARGET HIGH
US$41.00
0
STRONG BUY
15
BUY
8
HOLD
0
SELL
0
STRONG SELL
23
TOTAL · Buy
As of: 01/10/2026
Summit Therapeutics stock metrics
P/E
-13.06
P/B
18.07
EV/EBITDA
-13.17
RETURN ON EQUITY
-34.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
13.8%
FLOAT SHARES
110,351,158
AVG. DAILY VOLUME (30D)
6,834,106
Insider transactions (SEC)
Anand Bhaskar
Zanganeh Mahkam
DUGGAN ROBERT W
Soni Manmeet Singh
Zanganeh Mahkam
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.8%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Summit Therapeutics stock
What does Summit Therapeutics do?
Summit Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert W. Duggan, the company employs around 265 people.
The IPO was on 05/03/2015; the stock trades on NASDAQ under the ticker SMMT.
What do analysts say about Summit Therapeutics stock?
23 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$29.33, ranging from US$16.00 to US$41.00, with a median of US$30.00.
This is an external assessment, not a statement by Market Jury.
When does Summit Therapeutics report next?
The next earnings date is 19/10/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does Summit Therapeutics pay a dividend?
No, Summit Therapeutics currently does not pay a dividend.
Which stocks are comparable to Summit Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Halozyme Therapeutics.
How can I get Summit Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Summit Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.